Bioengineering strategies for next-generation female reproductive organoids: A roadmap to clinical translation

The human female reproductive system is characterized by highly dynamic tissue remodeling, cyclical endocrinology, and the precise orchestration of maternal–fetal immune tolerance. Historically, deciphering reproductive pathologies ranging from infertility to obstetric complications and malignancies has been hampered by the fundamental physiological and interspecies disparities inherent in 2D cultures and animal models. While three-dimensional (3D) organoid technology has initiated a paradigm shift, conventional static cultures relying on poorly defined, xenogeneic matrices (e.g., Matrigel) introduce profound immunogenic confounding factors and severe bioengineering bottlenecks. To bridge this gap, this review comprehensively delineates the advanced bioengineering strategies driving the next-generation of female reproductive models. We first outline foundational engineering pillars, highlighting the transition toward intelligent biomaterials, deterministic 3D bioprinting, and microfluidic microenvironments. Subsequently, we critically evaluate state-of-the-art organoid models across the ovary, fallopian tube, the maternal–fetal interface containing endometrium and placenta, cervix, and vagina. We emphasize how multi-lineage “assembloids” and multiorgan microphysiological systems successfully recapitulate transient implantation events and bidirectional endocrine crosstalk. Finally, we propose a strategic roadmap for the field, demonstrating how the integration of materials science, genetics, multi-omics, and engineering methods will overcome current limitations, ultimately accelerating the transition from benchtop in vitro models to standardized clinical diagnostics and reproductive regenerative therapeutics.